Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modakafusp Alfa plus Daratumumab SC in Relapsed or Refractory Multiple Myeloma (Phase 1/2a, Hungary)
2022-002169-14Phase 2Terminated
- Sponsor
- Takeda
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of modakafusp alfa and daratumumab in multiple myeloma (MM), sponsored by Takeda. Primary endpoints: Phase 1 safety and tolerability, Phase 1 pharmacokinetics and 2 more. Started Dec 2022; status: terminated.
02
Drugs
modakafusp alfadaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-002169-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002169-14.